A Double-Blind (3rd Party Open), Placebo-Controlled, Crossover, Dose Escalating Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Oral Doses Of PF-03716539, To Assess The Potential Of PF-03716539 To Inhibit CYP3A4 (In Vivo) And To Evaluate The Drug Interaction Potential Between PF-03716539 And Darunavir Or Maraviroc In Healthy Adult Subjects.

Trial Profile

A Double-Blind (3rd Party Open), Placebo-Controlled, Crossover, Dose Escalating Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Oral Doses Of PF-03716539, To Assess The Potential Of PF-03716539 To Inhibit CYP3A4 (In Vivo) And To Evaluate The Drug Interaction Potential Between PF-03716539 And Darunavir Or Maraviroc In Healthy Adult Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2009

At a glance

  • Drugs PF 3716539 (Primary) ; Darunavir; Maraviroc; Midazolam
  • Indications HIV infections
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 05 Jun 2009 Actual initiation date changed from Nov 2008 to Oct 2008 as reported by ClinicalTrials.gov.
    • 05 Jun 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Jun 2009 Actual patient number (37) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top